Introduction
Cervical cancer is the fourth most common cancer in women worldwide, accounting for 528 000 new cases and 266 000 deaths every year (1) . In Denmark, approximately 372 cervical cancers are diagnosed every year and 98 women die of the disease (2) . Cervical cancer is caused by human papilloma virus (HPV), which is a sexually transmitted virus (3) . Low-risk HPV genotypes may cause formation of anogenital warts. High-risk HPV (hrHPV) genotypes, such as HPV16 and 18, may cause cervical ª 2017 Nordic Federation of Societies of Obstetrics and Gynecology, Acta Obstetricia et Gynecologica Scandinavica 97 (2018) 142-150 dysplasia and cancer. In Denmark, the most common hrHPV genotypes in the general female population are HPV 16 (5.4%), HPV 52 (3.9%), HPV 31 (3.8%), HPV 51 (3.4%) and HPV 18 (2.4%) (4) . Approximately 74% of all cervical cancers are attributable to HPV 16 and/or HPV 18 (5) and an estimated 89% are attributable to HPV 16, HPV 18, HPV 31, HPV 33, HPV 45, HPV 52, and/or HPV 58 (4) .
It is well known that immunosuppressed women, such as solid organ recipients and individuals who are seropositive for human immunodeficiency virus (HIV), carry an increased risk of HPV-related disease, including cervical cancer (6) (7) (8) (9) . Unlike HIV sero-positive Danish women and transplant recipients in other developed countries, Danish women receiving immunosuppressive treatment, for example due to organ transplantation, are not recommended to have cervical cancer screening more frequently than women in the general population, nor are they recommended to have an HPV vaccination. Thus, the objective of this pilot study was to explore the hrHPV prevalence and genotype distribution in immunosuppressed women in order to evaluate the potential benefit of prophylactic HPV vaccination.
Material and methods

Study population
We designed a cross-sectional study, including a smaller prospective study, at Aarhus University Hospital, Denmark. Women included in this study were renal transplant recipients (RTR) and bone marrow transplant recipients (BMTR). Renal transplant recipients were enrolled in the period from 10 January 2014 to 31 December 2014 and bone marrow transplant patients were enrolled from 1 April 2014 to 31 December 2014. All women were included from outpatient clinics or wards at the Department of Renal Medicine and the Department of Hematology at Aarhus University Hospital and they all signed an informed consent form. Upon enrollment a validated questionnaire was sent to all women included in the study containing questions about socioeconomic status, lifestyle, sexual partners, gynecologic diseases, etc. Eligible women had to be ≥18 years old and to speak and understand Danish. Women with a history of hysterectomy were excluded. For the purpose of this study, the study group was divided in two groups.
Group 1: Women who underwent renal or bone marrow transplantation in 2014. All women had three cervical cytology samples performed; the first sample was obtained 30 days before or no later than a week after the transplantation, the second sample 1 month post-transplant, and the last sample 3 months post-transplant. Only women who had a sample taken at visit 1 and at least one sample taken at either visit 2 or 3 were included in the final analyses.
Group 2: Women who underwent renal or bone marrow transplantation during 2009-2012. These women had only one cervical cytology performed.
Cytological diagnosis
All cervical cytology samples were collected in SurePath Preservative Fluid and subsequently sent to the Department of Pathology, Randers Hospital, where the samples were examined for cytological abnormalities and tested for HPV. This department is specialized in processing cervical cytology samples and receives approximately 100 000 samples annually. The cytology diagnoses were graded according to the 2001 Bethesda classification (10) . For the purpose of this study we defined atypical squamous cells of undetermined significance (ASCUS) and low-grade squamous intraepithelial lesion (LSIL) as lowgrade disease. High-grade squamous intraepithelial lesion (HSIL), atypical squamous cells-cannot exclude HSIL (ASC-H), atypical glandular cells (AGC), and adenocarcinoma in situ (AIS) were defined as high-grade disease.
Information on previous screening history was obtained from the Danish Pathology Databank using the CPR number (i.e. unique identification number given to all Danish residents) of the participants. The Danish Pathology Databank was established in 1997 and contains information about examination procedures and pathology diagnoses. Most pathology departments have transferred information on cytology and histology specimens examined during 1978-1998; however, data prior to 1998 are considered incomplete.
HPV testing
Cervical specimens were analyzed for HPV using the 
Immunosuppressive therapy
All women included in this study were undergoing treatment with immunosuppressive drugs. Approximately 75% of the renal transplant recipients at Aarhus University Hospital received the standard immunosuppressive treatment: calcineurine inhibitor (tacrolimus), mycophenolatemofetil, corticosteroid, and an interleukin-2 receptor antagonist (basiliximab) as induction therapy. Approximately 25% received increased immunosuppressive regimen due to either ABO or HLA incompatibility. Bone marrow transplant recipients were treated with a calcineurine inhibitor (tacrolimus), mycophenolatmofetil, and corticosteroid to prevent Graft vs. Host disease.
HPV vaccination
In Denmark, vaccination with the quadrivalent HPV vaccine (i.e. HPV 6, 11, 16, and 18) 
Statistical analyses
Data were primarily analyzed descriptively due to a low sample size. The prevalence of hrHPV was calculated as the number of hrHPV-positive women divided by the total number of women, and the prevalence of abnormal cytology was calculated as the number of women with an abnormal cytology result divided by the total number of women. For women in group 1, we used the HPV test result and the cytology result of the sample obtained at visit 3 in our analyses.
The genotype-specific prevalence was calculated as the number of women positive for a given genotype with or without co-infection with other hrHPV genotypes divided by the total amount of women (n = 60). To evaluate the potential benefit of prophylactic HPV vaccination we calculated the prevalence of hrHPV types included in the HPV vaccines as the number of women positive for one or more hrHPV types included in the vaccines with or without co-infection with other genotypes not included in the vaccines, divided by total number of women (n = 60).
The Chi-square test and Fisher's exact test were applied on categorical data. A p-value <0.05 was considered statistically significant. Analyses were performed using STATA version 12 (StataCorp LP, College Station, TX, USA).
Ethical approval
This study was approved by the Danish Regional Ethics Committee (1-10-72-339-13) and the Danish Data Protection Agency (2007-58-0010).
Results
During 2014 we identified 129 female RTR and BMTR, of which 94 were eligible to participate; 60 women agreed to participate (63.8%) (Figures 1 and 2 ). The participation rate was lower in group 1 (51.3%) than in group 2 (72.7%). The overall median age at enrollment was 55.5 years [interquartile range (IQ) 48-65] and most women were RTR (Table 1) . For women in group 1, the median time from transplantation to the first cervical cytology was À1 day (IQ range À24 to 5).
The overall hrHPV prevalence among women in the study group was 15.0% [95% confidence intervals (CI) 7.1-26.6] ( Table 2 ). The hrHPV prevalence was higher in women undergoing bone marrow transplantation (29.4, 95% CI 10.3-56.0) than in women undergoing renal transplantation (9.3%, 95% CI 2.6-22.1), but this finding was only statistically significant in group 1 (0.0% vs. 42.9%, p = 0.03). There was no difference in hrHPV prevalence between group 1 and group 2 (15.0%, 95% CI 3.2-37.9 vs. 15.0%, 95% CI 5.7-29.8). Stratified by age, we noticed a slightly lower hrHPV prevalence among women aged <50 years (10.5%, 95% CI 1.3-33.1) and women aged 50-59 years (11.1%, 95% CI 1.4-34.7) than among women ≥60 years (21.7%, 95% CI 7.5-43.7). Furthermore, women ≤17 years at first intercourse were more likely hrHPV positive compared with women ≥18 years (p = 0.05). We observed a trend toward a higher hrHPV prevalence in women with ≥5 lifetime sex partners (21.4%; 95% CI 8.0-35.2) compared to women with ≤4 (8.7%; 95% CI 0.1-28.0), although this difference was not statistically significant (p = 0.21). Surprisingly, there was no difference in hrHPV prevalence when comparing women with a record of a previous abnormal cytology result with women without (p = 1.00).
As summarized in Table 3 , the genotype distribution was broad with HPV 45 (3.3%) as the most commonly detected genotype. None of the women tested positive for HPV 18 and only one woman tested positive for HPV 16 (1.7%). The prevalences of hrHPV genotypes included in the quadrivalent/bivalent HPV vaccines and the nonavalent HPV vaccine were 1.7 and 8.3%, respectively. Among hrHPV-positive women, the prevalences of hrHPV genotypes included in the bivalent/quadrivalent vaccines and the nonavalent vaccine were 10.0 and 50.0%, respectively. Of all women, 6.7% (n = 4) had single infections and 3.3% (n = 2) were infected with multiple types. In three women (5.0%) we were unable to perform specific genotyping and we therefore failed to determine whether the sample was positive for more than one genotype. Table 4 summarizes the hrHPV prevalence over time among women in group 1. None of the women was negative prior to transplantation and positive following transplantation. Three women (15.0%) showed signs of viral clearance (i.e. hrHPV-positive at visit 1 and negative at visit 2 or 3), and two women (10.0%) had a persistent hrHPV infection.
Of all women, 11.7% (95% CI 4.8-22.6) were diagnosed with an abnormal cervical cytology, with the majority being graded as low-grade disease (Table 5) . There was no difference in the prevalence of abnormal cytology when comparing BMTR with RTR or between group 1 and group 2.
Discussion
In this study we aimed to describe the hrHPV prevalence and genotype distribution in immunosuppressed women. The overall hrHPV prevalence among women was 15.0% and the hrHPV prevalence was higher in BMRT than in RTR, although the difference was not statistically significant. The most common hrHPV genotype was HPV 45 (3.3%). Among hrHPV-positive women the prevalences of hrHPV types included in the bivalent/quadrivalent and the nonavalent HPV vaccines were 10.0 and 50.0%, respectively. Based on very small numbers, we found no results supporting the hypothesis of viral reactivation following the initiation of immunosuppressive therapy.
We were quite surprised that the overall HPV prevalence in our study (15.0%) was lower than the HPV prevalence reported in a previous Danish study by Kjaer et al. (20.8%) (4) . We would have anticipated a higher HPV prevalence given that we only enrolled immunosuppressed women. However, comparison of our results with that of Kjaer et al. may not be strictly valid. It is well known that the HPV prevalence is higher among younger than older women, and the median age in our study (i.e. 55.5 years) was higher than in the previous Danish study (i.e. 37 years) (4, 13) . Nevertheless, the overall HPV prevalence reported in our study is in agreement with prevalence rates reported in the studies by Meeuwis et al. (14) and Mazanowska et al. (15) . Furthermore, previous case-control studies have found no significant difference in HPV prevalence in female RTR compared with healthy controls (16) . In the present study, we found that the HPV prevalence was higher in BMTR (29.4%) than in RTR (9.3%). This could be explained by the fact that BMTR are likely more immunosuppressed due to their cancer and the more aggressive treatment, similar to the reporting of HIV seropositive women with a low CD4-cell count being more likely to be HPV-positive than are women with a high CD4-cell count (17) . An important weakness of this study is the low sample size, thus interpretation of genotype distribution must be done with caution. The fact that only one woman was HPV16-positive and none were HPV 18-positive could be a coincidence. We cannot tell why we detected a large variety of hrHPV genotypes, but a hypothesis could be that the cervix might be more susceptible to the less aggressive types (for example HPV 35, 39, 53) due to the immunosuppressive therapy (18, 19) . This finding could also be a result of the high fraction of older women in our study group, as the HPV genotype distribution has been reported to differ by age. A systematic review as well as another Danish study have reported a significant decline in the prevalence of HPV16/18 in cervical cancer by age and an increase in the prevalence of non-HPV16/ 18 hrHPV genotypes (20, 21) . However, we acknowledge that our study results are based on the overall prevalence among immunosuppressed women and not on immunosuppressed women with cervical cancer. Since there is only little knowledge on the HPV genotype distribution among immunosuppressed women with cervical cancer, it cannot be inferred that the women in our study group carry a clinically relevant infection, meaning an infection that will lead to the development of cervical malignancy. Nevertheless, a persistent infection with oncogenic HPV genotypes in immunosuppressed women is likely associated with a higher risk of HPV-related disease, including dysplasia and cervical cancer, compared with immunecompetent individuals. Because the vast majority of women in our cohort were infected with HPV genotypes that are not included in the bivalent or quadrivalent vaccines (i.e. non HPV 16/18 genotypes), our study results indicate that the nonavalent HPV vaccine should be first choice in immunosuppressed women.
In the present study, the prevalence of low-grade disease (6.7%) was more than 50% higher than the prevalence in the general Danish population (4.1%), whereas the prevalence of high-grade disease was nearly threefold higher (5.0% vs. 1.8%) (4) . Previous studies have reported that immunosuppressed individuals, such as organ transplant recipients, are at increased risk of HPV infection and cervical dysplasia, but whereas the risk of HPV-related cancers such as head and neck cancer, vulvar, and vaginal cancer is increased in immunosuppressed individuals, the risk of cervical cancer does not seem to be significantly increased (22, 23) . Thus, these findings not only indicate that most cervical cancer cases among immunosuppressed individuals are likely avoided due to the detection and treatment of precancerous lesions through cervical cancer screening, but also highlight the need to HPV-vaccinate immunosuppressed individuals, as it is not possible to prevent other HPV-related cancers by screening.
Among women in group 1, we observed no incidents of infections or signs of viral reactivation in the months following transplantation. On contrary, 15% of the HPVpositive women cleared the HPV infection. Thus, in the present study, the initiation of immunosuppressive treatment did not seem to facilitate a viral reactivation, as hypothesized in previous clinical studies (8, 24) and as demonstrated in previous animal studies (25, 26) . However, we acknowledge that the lack of a positive correlation could be due to the low sample size, randomness, periodic variations of the HPV prevalence as reported by Liu et al. (27) , or because the HPV assays we used were not sensitive enough. A recent study found a significant increase in HPV prevalence following renal transplantation when using the highly sensitive HPV test SPF10-LiPA25 (28), whereas there was no significant increase when using the COBAS HPV test. In this study, samples were obtained several times over a two-year period after transplantation. Thus, it may be that a longer duration of immunosuppressive therapy is required for viral reactivation to occur; however, the findings of our study do not support this hypothesis, as there was no difference in HPV prevalence between group 1 and 2. This study has several limitations that must be addressed. The limited number of included women is a major limitation and indicates that our results should be interpreted with caution. Furthermore, we had an unexpected high rate of women who declined to participate (36.2%). We have no information on the individuals who declined to participate. All eligible women had severe courses of disease, but we cannot rule out that non-participants had poorer health and a lower socioeconomic status compared with participants. This may have affected our results by producing a lower HPV prevalence.
In conclusion, the overall hrHPV prevalence among organ transplant recipients was 15% and the prevalence tended to be higher among BMTR than RTR. The prevalence of high-grade cytological abnormalities was nearly threefold higher than found in previous studies of the general Danish female population. Because the vast majority of hrHPV-positive women were infected with non-HPV16/18 genotypes, the nonavalent vaccine will likely provide the best protection against HPV-related diseases.
